The Use of Post-transplantation Cyclophosphamide in Peripheral Blood HLA-matched Stem Cell Transplantation as Graft-versus-host Disease Prophylaxis in Patients With Malignant or Non-malignant Hematologic Disorders: A Single-center Experience of 52 Patients

被引:2
作者
Mahmoud, Hossam Kamel [1 ]
Fathy, Gamal Mohamed [2 ]
Elhaddad, Alaa [1 ]
Fahmy, Omar A. [3 ]
Abdel-Mooti, Mohamed [1 ]
Abdelfattah, Raafat [1 ]
Bokhary, Mahmoud [2 ]
机构
[1] Natl Canc Inst, Hematol & Bone Marrow Transplantat Unit, Cairo, Egypt
[2] Nasser Inst Hosp Res & Treatment, Hematol & Bone Marrow Transplantat Unit, Cairo, Egypt
[3] Cairo Univ, Fac Med, Hematol & Bone Marrow Transplantat Unit, Cairo, Egypt
关键词
aGVHD; cGVHD; HLA-matched; PTCY; Relapse; BONE-MARROW-TRANSPLANTATION; SEVERE APLASTIC-ANEMIA; ENGRAFTMENT KINETICS; MORTALITY; RECOVERY; OUTCOMES; AGENT;
D O I
10.1016/j.clml.2020.04.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was to assess the efficacy of post-transplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis in patients with malignant or non-malignant hematologic disorders who underwent allogenic hemopoietic stem cell transplantation. Fifty-two patients were enrolled in this study at Nasser Institute Hospital in Egypt. The 1-year incidence of acute GVHD and chronic GVHD was significantly lower than that of patients who received cyclosporine and methotrexate. Introduction: Studies addressing the utilization of post-transplant cyclophosphamide (CY) as graft-versus-host disease (GVHD) prophylaxis in allogeneic hemopoietic stem cell transplantation from matched sibling donors are limited and with controversial results. Chronic GVHD incidence necessitating systemic treatment is around 35% in peripheral blood stem cell transplantation (PBSCT) from human leukocyte antigen-matched sibling donors. Patients and Methods: In this study, high-dose CY was added to PBSCT aiming to reduce the incidence of GVHD to reach a lower figure compared with standard GVHD prophylaxis. Fifty-two patients with either benign or malignant hematologic disorders who underwent stem cell transplantation at Nasser Institute Hospital in Egypt from November 2017 to October 2018 were enrolled in this study. Fifty patients had fully human leukocyte antigen-matched siblings, whereas the remaining 2 patients had 1 locus class I mismatched donors. Pre-transplant conditioning regimen was fludarabine and busulfan (FLU/BU) in malignant cases (73.1%) and FLU/CY in benign hematologic disorders (26.9%) and 1 patient with hypocellular myelodysplastic syndrome. For GVHD prophylaxis, CY was given at a dose of 50 mg/kg/day on days 3 and 4 post-transplantation, and cyclosporine (CSA) starting day 5 in 96.1% of patients. For the 1-locus mismatched patients, both CSA and mycophenolate mofetil were administered starting day 5. Results: The 1-year incidence of acute GVHD (aGVHD) was 15.3% and for chronic GVHD (cGVHD) was 13.4%. Historical data of GVHD prophylaxis at our center using CSA and methotrexate showed an incidence of 37% for aGVHD and 33.9% for cGVHD. Conclusions: Post-transplant CY GVHD prophylaxis led to significantly less aGVHD (P = .03) and cGVHD (P = .04). (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:677 / 684
页数:8
相关论文
共 31 条
[21]  
Mielcarek M, 2016, BLOOD, V127, P1502, DOI [10.1182/blood-2015-10672071, 10.1182/blood-2015-10-672071]
[22]   Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease [J].
Modi, Badri ;
Hernandez-Henderson, Michael ;
Yang, Dongyun ;
Klein, Jeremy ;
Dadwal, Sanjeet ;
Kopp, Erin ;
Huelsman, Karen ;
Mokhtari, Sally ;
Ali, Haris ;
Al Malki, Monzr M. ;
Spielberger, Ricardo ;
Salhotra, Amandeep ;
Parker, Pablo ;
Forman, Stephen ;
Nakamura, Ryotaro .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (02) :265-269
[23]   Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil [J].
Moiseev, Ivan S. ;
Pirogova, Olga V. ;
Alyanski, Alexandr L. ;
Babenko, Elena V. ;
Gindina, Tatyana L. ;
Darskaya, Elena I. ;
Slesarchuk, Olga A. ;
Bondarenko, Sergey N. ;
Afanasyev, Boris V. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (06) :1037-1042
[24]   Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation [J].
Przepiorka, D ;
Smith, TL ;
Folloder, J ;
Khouri, I ;
Ueno, NT ;
Mehra, R ;
Körbling, M ;
Huh, YO ;
Giralt, S ;
Gajewski, J ;
Donato, M ;
Cleary, K ;
Claxton, D ;
Braunschweig, I ;
van Besien, K ;
Andersson, BS ;
Anderlini, P ;
Champlin, R .
BLOOD, 1999, 94 (04) :1465-1470
[25]  
Raj K, 2014, BIOL BLOOD MARROW TR, V20, P1875, DOI [10.1016/j.bbmt.2014.10.005, 10.1016/j.bbmt.2014.03.003]
[26]   Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission:: Results of a European survey [J].
Rocha, V ;
Labopin, M ;
Gluckman, E ;
Powles, R ;
Arcese, W ;
Bacigalupo, A ;
Reiffers, J ;
Iriondo, A ;
Ringdén, O ;
Ruutu, T ;
Frassoni, F .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4324-4330
[27]   Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation [J].
Shah, Mithun Vinod ;
Saliba, Rima M. ;
Rondon, Gabriela ;
Chen, Julianne ;
Soebbing, Doris ;
Rus, Ioana ;
Alousi, Amin ;
Oran, Betul ;
Kebriaei, Partow ;
Qazilbash, Muzaffar ;
Parmar, Simrit ;
Hosing, Chitra ;
Khouri, Issa F. ;
Popat, Uday R. ;
Champlin, Richard E. ;
Ciurea, Stefan O. .
BONE MARROW TRANSPLANTATION, 2019, 54 (04) :601-606
[28]   Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression [J].
Wachsmuth, Lucas P. ;
Patterson, Michael T. ;
Eckhaus, Michael A. ;
Venzon, David J. ;
Gress, Ronald E. ;
Kanakry, Christopher G. .
JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (06) :2357-2373
[29]   Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland [J].
Wolff, Daniel ;
Hilgendorf, Inken ;
Wagner-Drouet, Eva ;
Jedlickova, Zuzana ;
Ayuk, Francis ;
Zeiser, Robert ;
Schaefer-Eckart, Kerstin ;
Gerbitz, Armin ;
Stadler, Michael ;
Klein, Stefan ;
Middeke, Jan-Moritz ;
Lawitschka, Anita ;
Winkler, Julia ;
Halter, Jorg ;
Holler, Ernst ;
Kobbe, Guido ;
Stelljes, Matthias ;
Ditschkowski, Markus ;
Greinix, Hildegard .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (07) :1450-1455
[30]   Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT [J].
Yang, Yingying ;
Hu, Yongxian ;
Huang, He .
REGENERATIVE THERAPY, 2019, 11 :139-142